SRSarepta Therapeutics SRPT · NASDAQ
$17.10 -3.88% (-$0.69)
- Market cap
- $1.88B
- Enterprise value
- $2.35B
- P/E
- -
- Forward P/E
- 5.5x
- PEG
- -
- P/S
- 1.0x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -5.6%
- Gross margin
- 58.6%
- Net margin
- -6.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.21
- Free float
- 95.1%
About the company
Sarepta Therapeutics, Inc. (SRPT) is an American biopharmaceutical company focused on research, development, and commercialization of drugs for the treatment of rare genetic diseases. The company specializes in treating muscular dystrophies caused by genetic mutations. Sarepta Therapeutics develops innovative therapies based on gene therapy and RNA technologies, which have the potential to provide new treatment options for patients with rare genetic diseases. With its successful research programs and collaboration with renowned experts in the field, the company has become a significant player in the field of muscular dystrophy treatment. Shares of Sarepta Therapeutics, Inc. (SRPT) can represent an interesting investment opportunity for those seeking exposure to the biotechnology industry with a focus on treating rare genetic diseases and innovative therapeutic approaches.
Sector
Healthcare
Industry
Biotechnology
CEO
Michael E. Severino
Employees
835
Headquarters
Cambridge
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number